Skip to main content

Table 2 PRO-CTCAE item intraclass correlation by tablet, IVRS and paper modes of administration

From: Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

PRO-CTCAE Item ICC (95 % CI)
  Mode Equivalence Test – Retesta
  Tablet vs. IVRS Tablet vs. Paper IVRS vs. Paper Tablet vs. Tablet
Anxiety (F) 0.77 (0.68–0.83) 0.76 (0.67–0.83) 0.72 (0.61–0.79) 0.78 (0.68–0.85)
Anxiety (S) 0.75 (0.65–0.82) 0.72 (0.62–0.80) 0.73 (0.63–0.80) 0.70 (0.58–0.80)
Anxiety (I) 0.69 (0.58–0.77) 0.74 (0.64–0.81) 0.68 (0.57–0.77) 0.83 (0.75–0.89)
Constipation (S) 0.71 (0.60–0.79) 0.76 (0.66–0.83) 0.80 (0.73–0.86) 0.83 (0.74–0.89)
Decreased appetite (S) 0.73 (0.62–0.80) 0.80 (0.72–0.86) 0.82 (0.73–0.87) 0.81 (0.71–0.87)
Decreased appetite (I) 0.78 (0.69–0.84) 0.80 (0.72–0.86) 0.70 (0.60–0.79) 0.80 (0.71–0.87)
Fatigue, tiredness, or lack of energy (S) 0.74 (0.64–0.81) 0.76 (0.67–0.83) 0.74 (0.64–0.81) 0.77 (0.66–0.85)
Fatigue, tiredness, or lack of energy (I) 0.65 (0.53–0.75) 0.70 (0.59–0.79) 0.60 (0.46–0.70) 0.79 (0.69–0.86)
Insomnia (S) 0.83 (0.76–0.88) 0.94 (0.92–0.96) 0.79 (0.71–0.85) 0.65 (0.50–0.76)
Insomnia (I) 0.76 (0.67–0.83) 0.84 (0.77–0.89) 0.81 (0.74–0.87) 0.72 (0.59–0.81)
Loose or watery stools (F) 0.80 (0.73–0.86) 0.81 (0.74–0.87) 0.76 (0.67–0.83) 0.55 (0.38–0.69)
Mouth or throat sores (S) 0.82 (0.75–0.87) 0.87 (0.82–0.91) 0.71 (0.61–0.79) 0.82 (0.73–0.88)
Mouth or throat sores (I) 0.55 (0.41–0.67) 0.62 (0.48–0.72) 0.61 (0.47–0.71) 0.81 (0.72–0.87)
Nausea (F) 0.87 (0.81–0.91) 0.90 (0.85–0.93) 0.87 (0.82–0.91) 0.79 (0.70–0.86)
Nausea (S) 0.85 (0.78–0.89) 0.87 (0.82–0.91) 0.86 (0.80–0.90) 0.84 (0.76–0.89)
Numbness/tingling in hands/feet (S) 0.89 (0.85–0.92) 0.89 (0.84–0.92) 0.86 (0.81–0.91) 0.80 (0.70–0.86)
Numbness/tingling in hands/feet (I) 0.81 (0.73–0.86) 0.85 (0.79–0.90) 0.80 (0.73–0.86) 0.55 (0.37–0.68)
Pain (F) 0.90 (0.86–0.93) 0.93 (0.90–0.95) 0.91 (0.87–0.94) 0.83 (0.75–0.89)
Pain (S) 0.88 (0.83–0.92) 0.89 (0.85–0.92) 0.86 (0.81–0.90) 0.82 (0.73–0.88)
Pain (I) 0.77 (0.68–0.84) 0.83 (0.77–0.88) 0.77 (0.68–0.83) 0.84 (0.76–0.89)
Sad or unhappy feelings (F) 0.77 (0.68–0.83) 0.80 (0.72–0.85) 0.76 (0.67–0.83) 0.73 (0.61–0.81)
Sad or unhappy feelings (S) 0.77 (0.69–0.84) 0.79 (0.71–0.85) 0.79 (0.71–0.85) 0.63 (0.48–0.75)
Sad or unhappy feelings (I) 0.69 (0.58–0.78) 0.70 (0.59–0.78) 0.72 (0.61–0.80) 0.76 (0.65–0.84)
Shortness of breath (S) 0.85 (0.79–0.89) 0.87 (0.82–0.91) 0.90 (0.85–0.93) 0.70 (0.56–0.80)
Shortness of breath (I) 0.84 (0.77–0.89) 0.73 (0.63–0.81) 0.72 (0.61–0.80) 0.66 (0.52–0.77)
Vomiting (F) 0.82 (0.75–0.87) 0.96 (0.94–0.97) 0.87 (0.82–0.91) 0.81 (0.72–0.88)
Vomiting (S) 0.82 (0.75–0.87) 0.92 (0.88–0.94) 0.83 (0.76–0.88) 0.79 (0.70–0.86)
  1. Note: The mode equivalence of the presence/absence item assessing rash was evaluated with Kappa statistics and results are reported in the text
  2. Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, F Frequency, S Severity, I Interference, ICC Intraclass Correlation Coefficient, CI Confidence Interval, IVRS Interactive Voice Response System
  3. aTest-retest data were obtained from the validation study [3] (see Methods)